Short Interest in uniQure (NASDAQ:QURE) Increases By 22.8%

uniQure (NASDAQ:QURE) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 3,180,000 shares, a growth of 22.8% from the June 30th total of 2,590,000 shares. Based on an average daily volume of 2,730,000 shares, the short-interest ratio is currently 1.2 days.

uniQure Stock Performance

Shares of QURE stock traded down $0.23 during mid-day trading on Friday, hitting $8.34. The stock had a trading volume of 733,674 shares, compared to its average volume of 7,658,339. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35. The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70. The company’s 50-day simple moving average is $5.75 and its 200-day simple moving average is $5.48.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The business had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%. As a group, sell-side analysts anticipate that uniQure will post -4.4 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently made changes to their positions in the stock. Raymond James & Associates grew its position in uniQure by 6.4% during the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock worth $354,000 after buying an additional 3,145 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 58.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after buying an additional 3,664 shares during the last quarter. Pale Fire Capital SE boosted its position in shares of uniQure by 9.2% in the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after buying an additional 5,500 shares in the last quarter. Clear Harbor Asset Management LLC increased its holdings in uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 12,500 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in uniQure during the fourth quarter worth about $86,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on QURE shares. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, July 9th. Mizuho cut their price target on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $23.50.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.